Alphatec Holdings, Inc. Reports Third Quarter 2026 Financial Results and Revises Full-Year Guidance

Alphatec Holdings reported third-quarter 2026 revenue of $221 million, below analysts’ $225 million estimate, and adjusted earnings of 9 cents per share versus the 10-cent consensus. Management cited weaker cross-selling, including reduced use of high-margin biologics in spinal fusion procedures, as well as industry softness and lower-than-expected mid-to-lower back surgery volumes. The company lowered its 2026 revenue guidance to approximately $862 million from $882 million.